Tetrac (Standard)
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98%
- No. CAS: 67-30-1
- Fòrmula: C14H8I4O4
- Peso molecular:747.83
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureza y Documentación
-
Help & FAQs
-
HY-W008859
Tetrac -
HY-A0070A
LiothyronineTIGIT/PVR Blocker -
HY-W010696
Reverse T3Thyroid Hormone -
HY-A0070AG
Liothyronine (GMP)TRα/TRβ Agonist (GMP) -
HY-A0070AR
Liothyronine (Standard)TRα/TRβ Agonist -
HY-D0083
DiIFluorescent Dye -
HY-W010696R
Reverse T3 (Standard)Thyroid Hormone -
HY-A0070
Liothyronine sodiumTRα/TRβ Agonist -
HY-B1201
TiratricolThyroid Hormone Receptor Inhibitor -
HY-A0070R
Liothyronine sodium (Standard)TRα/TRβ Agonist -
HY-15930A
TMB dihydrochlorideChromogenic Agent -
HY-DY1012
DiI (solution)Fluorescent Dye
Product Information
Information
Aplicación
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
No. CAS 67-30-1
-
Peso molecular 747.83
-
Fòrmula C14H8I4O4
-
SMILES
O=C(O)CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1
-
Synonyms
Tetraiodothyroacetic acid (Standard); 3,3',5,5'-Tetraiodothyroacetic acid (Standard)
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Schmohl KA, et, al. Tetrac as an anti-angiogenic agent in cancer. Endocr Relat Cancer. 2019 Jun 1; 26(6):R287-R304. [Content Brief]
[2]. Davis PJ, et, al. Nongenomic Actions of Thyroid Hormone: the Integrin Component. Physiol Rev. 2020 Jun 25. [Content Brief]
[3]. Chin YT, et, al. Tetrac and NDAT Induce Anti-proliferation via Integrin αvβ3 in Colorectal Cancers With Different K-RAS Status. Front Endocrinol (Lausanne). 2019 Mar 12; 10:130. [Content Brief]
[4]. Ashur-Fabian O, et, al. Tetrac Delayed the Onset of Ocular Melanoma in an Orthotopic Mouse Model. Front Endocrinol (Lausanne). 2019 Jan 8; 9:775. [Content Brief]
[5]. Rajabi M, et, al. Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer. Bioorg Med Chem Lett. 2018 Apr 15;28(7):1223-1227. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tetrac (Standard) Related Classifications
HY-W008859R Related Classifications
Powered by Bioz